From Antibodies To Vaccines: How Prestige BioPharma Is Shaping Its Future
Asia Axes In Korea, Singapore
The vice-chairman of Singapore-based Prestige Group talks to Scrip about the biopharma's strategies in Asia and elsewhere, as it focuses on vaccines for COVID-19 and other diseases, along with novel antibody therapeutics in oncology and biosimilars.
You may also be interested in...
South Korea is making a strategic push to strengthen its vaccine capabilities, with a focus on COVID-19 and future pandemics and the aim of becoming a global development hub. But one expert told a recent meeting that these goals should not overshadow the government’s original aim of becoming self-sufficient for the national immunization program.
Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.
At a recent forum in Seoul, SK Group unveiled its biotech investment strategy and noted the next few years could present multiple major opportunities for Korean biotechs.